Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 13, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements within the GlaxoSmithKline Employee Trust ("the GSK Trust") on February 9, 2006:
- Sale: Abacus (GSK) Trustees Limited sold 4,444 Ordinary Shares on behalf of participants in the SmithKline Beecham Mid-Term Incentive Plan at a price of GBP 14.98 per share.
- Transfer: Abacus (GSK) Trustees Limited transferred 6,391 Ordinary Shares to participants in the same incentive plan.
Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the GSK Trust in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the aforementioned share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of shares sold (4,444) and transferred (6,391) under the SmithKline Beecham Mid-Term Incentive Plan.
- Confirm the transaction price of GBP 14.98 per share for the sale executed on February 9, 2006.
- Note that the GSK Trust is a discretionary trust benefiting current and former employees, including three named directors.
- Confirm that this filing does not contain financial results or strategic updates for the period.